DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
Los Angeles, CA - (NewMediaWire) - April 13, 2021 - The Schall Law Firm, a national shareholder rights litigation
firm, reminds investors of a class action lawsuit against bluebird
bio, Inc. (“bluebird” or “the Company”) (NASDAQ: BLUE) for violations of §§10(b) and 20(a) of the
Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the
U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities
between May 11, 2020 and November 4, 2020, inclusive (the ''Class Period''),
are encouraged to contact the firm before April 13, 2021.
We also encourage you to contact Brian Schall of
the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067,
at 310-301-3335, to discuss your rights free of charge. You can also reach us
through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The class, in this case, has not yet been
certified, and until certification occurs, you are not represented by an
attorney. If you choose to take no action, you can remain an absent class
member.
According to the Complaint, the Company made
false and misleading statements to the market. Bluebird presented insufficient
data to support its U.S. Biologics Licensing Application (“BLA”) submission for
LentiGlobin for sickle cell disease (“SCD”). The Company downplayed the risk of
disruptions related to the COVID-19 pandemic to its BLA submission schedule for
LentiGlobin for SCD, especially on the topic of manufacturing. Based on these
facts, the Company’s public statements were false and materially misleading
throughout the class period. When the market learned the truth about bluebird,
investors suffered damages.
(NewMediaWire) - April 13, 2021 - The Schall Law Firm, a national shareholder rights litigation
firm, reminds investors of a class action lawsuit against bluebird
bio, Inc. (“bluebird” or “the Company”) (NASDAQ: BLUE) for violations of §§10(b) and 20(a) of the
Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the
U.S. Securities and Exchange Commission.
